# Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome

> **NCT03695822** · PHASE4 · WITHDRAWN · sponsor: **Far Eastern Memorial Hospital**

## Conditions studied

- Overactive Bladder Syndrome

## Interventions

- **DRUG:** Mirabegron 25mg

## Key facts

- **NCT ID:** NCT03695822
- **Lead sponsor:** Far Eastern Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-12-24
- **Primary completion:** 2019-01-21
- **Final completion:** 2019-01-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** I did not pass the 2018 Ministry of Science and Technology research project subsidy, so I applied for the project to close the case.
- **Last updated:** 2019-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03695822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03695822, "Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03695822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*